Skip to main content
Clinical Trials/NCT00272753
NCT00272753
Completed
Phase 4

A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementary Value of the Budesonide Component Within Symbicort When Tested in a Model of Slow Onset Acute Asthma

AstraZeneca1 site in 1 country20 target enrollmentApril 2004

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Asthma
Sponsor
AstraZeneca
Enrollment
20
Locations
1
Primary Endpoint
The decrease in lung function (FEV1) after the third AMP provocation test.
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day

Registry
clinicaltrials.gov
Start Date
April 2004
End Date
November 2005
Last Updated
14 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • asthma diagnosis according to ATS criteria,
  • lung function (FEV1) above 60% of predicted,
  • AMP-PC20 below 160 mg/ml with a documented fall in FEV1 of 30% in this provocation test

Exclusion Criteria

  • having smoked \> 10 Pack-years,
  • hypersensitivity to one of the study drugs,
  • significant co-morbidity, pregnancy or lactating

Outcomes

Primary Outcomes

The decrease in lung function (FEV1) after the third AMP provocation test.

Secondary Outcomes

  • Decrease in lung function (FEV1) after the second AMP provocation test,
  • lung function and Borg Score over the test day,
  • increase in FEV1 at three minutes after study drug inhalation,
  • time course of recovery from the AMP-induced decrease in lung function

Study Sites (1)

Loading locations...

Similar Trials